30 Day Trial

BARE BONES content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Product / Company Performance

Camber Spine Announces 1Q19 Sales Results of +22% vs. 1Q18 -

Camber Spine announced 1Q19 preliminary proprietary sales results of +22% vs. 1Q18. (Proprietary sales refers to products innovated and owned by the company.) Growth was largely driven by continuing adoption of SPIRA and ENZA products, which grew +97% vs. the prior year. The company has plans to launch a device for sacroiliac joint repair, an expandable TLIF spacer and custom implant options to bolster its portfolio. Camber Spine anticipates receiving a CE mark for SPIRA later this year. (Camber Spine, 5/20/19)

This article is a Member-only item of content. Members, please log in to read the complete post.
If you are not yet a Member, click here to learn more about purchasing ORTHOWORLD Membership.